Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

Q4 2024 Earnings Call Transcript March 12, 2025 Harvard Bioscience, Inc. beats earnings expectations. Reported EPS is $0.06, ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...

Thank you for joining us to discuss LifeMD Inc fourth-quarter and full-year 2024 earnings results. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

The major indexes suffered another week of sharp losses as Trump tariffs ramped up, shrugging off tame inflation.

EU mid-market update: US futures stabilize after Monday rout; Oversold indicators flashing as draw-down comparisons are made; ...